Global Prurigo Nodularis Treatment Market - 2023-2030

Market Overview

The Global Prurigo Nodularis Treatment Market size reached US$ 964.3 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 1.1 billion by 2030. The Global Prurigo Nodularis Treatment Market is exhibiting at a CAGR of 3.7% during the forecast period 2023-2030.

Prurigo Nodularis is a chronic skin condition with itchy nodules. Treatment of prurigo Nodularis aims to reduce itching, inflammation, and the formation of nodules, but there is no universally accepted standard of care. Treatment options are limited and there is no widely accepted standard of care. Collaboration between healthcare providers, researchers, pharmaceutical companies, and patient advocacy groups is essential for prurigo nodularis treatment.

The prurigo nodularis treatment market is driven by factors such as the increasing prevalence of prurigo nodularis, increasing demand for capsaicin cream, advancements and innovations in treatment options, increasing adoption of emollients, growing interest in targeted therapies and biologics, and technological advancements.

Market Dynamics

Increasing Demand for Capsaicin Cream

The increasing demand for capsaicin cream is a significant factor driving the market share in the Prurigo Nodularis Treatment Market during the forecast period. Capsaicin cream can be used as part of a comprehensive treatment approach for prurigo nodularis. It can be used alongside other topical or systemic medications, such as corticosteroids or antihistamines, to enhance symptom relief and improve overall management of the condition.

For instance, In many regions, capsaicin cream is available over the counter without a prescription. This accessibility makes it a convenient option for patients seeking self-management of prurigo nodularis symptoms or those who prefer non-prescription treatments.

High Cost of Treatment

High treatment costs can limit access to effective therapies for prurigo nodularis, particularly for individuals who may not have adequate insurance coverage or financial resources. This can lead to a smaller patient population being able to access and afford the available treatment options. Some treatments may require long-term use, which can become burdensome for patients over time, leading to non-adherence to treatment regimens or suboptimal treatment outcomes.

High treatment costs can strain healthcare systems, especially in regions with publicly funded healthcare or insurance systems. Limited healthcare budgets may restrict access to costly treatments, affecting the availability and coverage of Prurigo Nodularis Treatments

COVID-19 Impact Analysis

The COVID-19 pandemic has led to disruptions in healthcare services worldwide. Non-urgent medical appointments and elective procedures, including dermatology consultations, have been postponed or canceled in many regions. This has affected the diagnosis and management of prurigo nodularis, potentially delaying patient treatment access.

The pandemic has resulted in changes in patient behavior, including reduced healthcare-seeking conduct due to concerns about potential exposure to the virus. Patients with prurigo nodularis may have postponed or avoided seeking medical attention or follow-up visits, leading to underdiagnosis and undertreatment.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict and its associated challenges may divert resources and attention from research and development activities related to prurigo nodularis. Funding and focus on medical research may shift towards more immediate priorities, impacting the progress of new treatment options or clinical trials for prurigo nodularis.

The conflict can have broader socioeconomic impacts, affecting individuals' and healthcare systems' financial stability and resources. Economic instability, loss of livelihoods, and displacement can result in limited financial resources for patients and healthcare providers, impacting the affordability and availability of prurigo nodularis treatments.

Segment Analysis

The Global Prurigo Nodularis Treatment Market is segmented based on product, distribution channel, and region.

Based on the Product, the Corticosteroids Segment is Expected to Dominate the Market Share

The corticosteroid market held 35.6% of the Global Prurigo Nodularis Treatment Market share in 2022. Corticosteroids have demonstrated effectiveness in managing the symptoms of prurigo nodularis, including reducing itching, inflammation, and the formation of nodules. They provide quick relief and are often prescribed as first-line treatments.

Corticosteroids are often combined with other treatments, such as emollients or topical immune modulators, to enhance the overall management of prurigo nodularis. Corticosteroids are generally more cost-effective than other treatment options, making them accessible to a wide range of patients. This affordability aspect also contributes to their market dominance.

For instance, in March 2023, statistically significant and clinically meaningful improvements were seen among adult patients who have prurigo nodularis (PN) following their treatment with dupilumab (Dupixent) over 24 weeks in the randomized, double-blind, placebo-controlled phase 3 LIBERTY PN-PRIME and LIBERTY PN-PRIME2 trials.

Geographical Analysis

North America Holds the Largest Market Share due to the Large Patient Population and Advanced Healthcare Infrastructure.

North America holds the 42.7% market share for the prurigo nodularis treatment market in 2022 due to the large patient population and advanced healthcare infrastructure. North America has a substantial patient population, including a high prevalence of prurigo nodularis cases. The large patient base creates a demand for effective treatments and contributes to the market's growth.

North America is known for its advanced healthcare infrastructure, including well-established medical facilities, specialized dermatology centers, and access to advanced diagnostic tools. This infrastructure supports accurate diagnosis and effective treatment of prurigo nodularis, driving the market's growth.

Competitive Landscape

The major global players include: Menlo Therapeutics Inc., Pfizer Inc, Sanofi S.A., Kiniksa Pharmaceuticals Ltd., Astellas Pharma Inc, Eli Lilly and Company, GlaxoSmithKline, Galderma S.A., Trevi Therapeutics Inc, and Regeneron Pharmaceuticals Inc.

Why Purchase the Report?

• To visualize the Global Prurigo Nodularis Treatment Market segmentation based on product, distribution channel, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous prurigo nodularis treatment market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Prurigo Nodularis Treatment Market Report Would Provide Approximately 54 Tables, 46 Figures And 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies